Axogen (AXGN) vs Establishment Labs (ESTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Axogen (AXGN) has outperformed Establishment Labs (ESTA) over the past year, gaining 113.3% versus a gain of 57.8%. Over five years, AXGN leads with a +164.6% price change compared with -17.1% for ESTA. Axogen is the larger company by market cap ($2.11 billion vs $1.90 billion), about 1.1 times the size.
On valuation, Axogen trades at a lower forward P/E (52.4x vs 1064.2x for Establishment Labs).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | ESTA |
|---|---|---|
| Share price | $36.04 | $63.85 |
| Market cap | $2.11B | $1.90B |
| 1-day change | -0.74% | -2.21% |
| YTD return | +10.11% | -12.39% |
| 1-year return | +113.25% | +57.85% |
| 5-year return | +164.61% | -17.08% |
| Forward P/E | 52.38 | — |
| EPS (TTM) | $-0.67 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.91 | $97.59 |
| 52-week low | $15.27 | $38.38 |
| Distance from 52-week high | -31.88% | -34.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +49.33% | +60.44% |
| Average volume | 1.22M | 426.60K |
| Shares outstanding | 58.67M | 29.80M |
| Employees | 622 | 1,004 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXGN has outperformed ESTA by 55.4 percentage points over the past year.
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Healthcare · Medical Devices · 622 employees
About Establishment Labs
ESTA stock →Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Healthcare · Medical Devices · 1,004 employees
AXGN vs ESTA FAQ
Which is bigger, Axogen or Establishment Labs?
Axogen (AXGN) is larger, with a market capitalization of $2.11B compared with $1.90B for Establishment Labs (ESTA).
Which stock has performed better over the past year, AXGN or ESTA?
AXGN returned +113.25% over the past 12 months, compared with +57.85% for ESTA (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and Establishment Labs in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.